Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Lucy Scientific Discovery Inc LSDIF

Lucy Scientific Discovery Inc. is an early stage psychotropics contract manufacturing company. The Company is engaged in researching, developing, and manufacturing psychotropic drugs. The Company is a manufacturer of controlled compounds dedicated to advancing the frontiers of mind science and facilitating the development of psychotropic and psychedelic treatment therapies. It is focused on developing therapies for patients in need, and through its lead candidate SANA-013, dedicated to advancing the understanding and applications of psychedelic medicine, improving mental health outcomes, and enhancing well-being for individuals worldwide. The Company is engaged in the production of a variety of natural, synthetic, and biosynthetic products to meet the needs of the psychotropics-based medicines market. Its products are in the form of raw materials, crude extracts, targeted formulations, single molecule fractions, and white- and private-label products.


GREY:LSDIF - Post by User

Post by Stockslayeron May 29, 2023 3:56pm
39 Views
Post# 35469187

SIGNIFICANT MARKET OPPORTUNITY.

SIGNIFICANT MARKET OPPORTUNITY.
Did you know that around 3.8% of the global population or around 280 million people suffer from depressive  disorders. MDD is a mood disorder that causes a persistent feeling of sadness and loss of interest in normal 
activities. It is estimated that MDD affects 7.1% of the adult population in the U.S. and around 10% of the adult  population in Canada. Johns Hopkins Medicine researchers report that two doses of the psychedelic substance  psilocybin, given with supportive psychotherapy, produced rapid, and significant reductions in depressive  symptoms. 
<< Previous
Bullboard Posts
Next >>